GoKawiilMerck to Acquire Silence Therapeutics for $1.3 Billion
GoKawiil Brief
Germany's Merck has agreed to buy UK-based Silence Therapeutics, offering $20 in cash per American depositary share. The offer represents more than double Silence Therapeutics' closing share price as of the prior Friday.
Why It Matters
GoKawiil's interpretation of the reporting above, not reported fact.
The large premium suggests Merck sees significant value in Silence Therapeutics' RNA interference technology or pipeline that the market had not priced in. This deal could expand Merck's capabilities in RNA-based therapeutics, a growing area of biotech investment.
Key Takeaways
- Merck is paying $1.3 billion to acquire Silence Therapeutics.
- The $20 per share cash offer is more than double Friday's closing price.
- The deal signals continued consolidation in the RNA therapeutics sector.
Source: wsj.com, 2026-10-19
Published there as: “Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.Get alerts for these topics